Johnson & Johnson (JNJ)vsTrinity Biotech plc (TRIB)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
TRIB
Trinity Biotech plc
$0.60
0.00%
HEALTHCARE · Cap: $12.18M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 198298% more annual revenue ($96.36B vs $48.57M). JNJ leads profitability with a 21.8% profit margin vs -75.9%. TRIB appears more attractively valued with a PEG of 1.30. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
TRIB
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+85.1%
Fair Value
$5.52
Current Price
$0.60
$4.92 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
ROE of -1913.0% — below average capital efficiency
Revenue declined 5.5%
Earnings declined 77.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : TRIB
PEG of 1.30 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : TRIB
The primary concerns for TRIB are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TRIB is a turnaround play — different risk/reward profiles.
TRIB carries more volatility with a beta of 0.79 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 27/100), backed by strong 21.8% margins. TRIB offers better value entry with a 85.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Trinity Biotech plc
HEALTHCARE · MEDICAL DEVICES · USA
Trinity Biotech plc acquires, develops, manufactures and markets medical diagnostic products for the clinical laboratory and point of care (POC) segments of the diagnostic market in the United States, Africa, Asia and Europe. The company is headquartered in Bray, Ireland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?